Krystal Biotech is trading 4.5% down at $347.19 as the stock gives back recent gains amid a broader pullback in high-beta biotech names.
- The decline follows a period of record highs supported by strong Vyjuvek fundamentals and positive Q1 2026 results, with no new company-specific news reported this morning.
- The move appears tied to a sector-wide trend, as the SPDR S&P Biotech ETF has dropped approximately 2.5% during the current pullback phase.